Humanigen, Inc. (HGENQ)
| Market Cap | 23.82K |
| Revenue (ttm) | 1.70M |
| Net Income (ttm) | -53.63M |
| Shares Out | 119.08M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 290,023 |
| Open | 0.0020 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0020 |
| 52-Week Range | n/a |
| Beta | -1.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About HGENQ
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of ... [Read more]
Financial Performance
In 2022, Humanigen's revenue was $2.51 million, a decrease of -30.07% compared to the previous year's $3.60 million. Losses were -$70.73 million, -70.11% less than in 2021.
Financial StatementsNews
COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy
Drug developer Humanigen HGEN.PK has filed for voluntary Chapter 11 bankruptcy, according to a court filing, after struggling to get regulatory approval for its COVID-19 treatment.
Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high...
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon ...
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia
CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosis Eleven subjects dosed with lenzilumab and with current standard of care, azacitidine S...
Humanigen Reports Third Quarter 2022 Financial Results
Short Hills, New Jersey--(Newsfile Corp. - November 14, 2022) - Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first...
Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference
Short Hills, New Jersey--(Newsfile Corp. - November 10, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain infl...
Humanigen Announces Retention of SC&H Capital as Financial Advisor
Short Hills, New Jersey--(Newsfile Corp. - October 31, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating certain infla...
Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML
Additional Clinical Sites Expected to Enroll CMML Patients in AustraliaShort Hills, New Jersey and Adelaide, South Australia--(Newsfile Corp. - September 12, 2022) - Humanigen, Inc. (Nasdaq: HGEN), Hu...
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 9, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humanigen, Inc. ...
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humanigen, Inc. ...
Humanigen, Inc. Shareholder News: Robbins LLP is Investigating Humanigen, Inc. (HGEN) on Behalf of Investors
SAN DIEGO--(BUSINESS WIRE)---- $HGEN #COVID19--Humanigen accused of overstating the clinical and commercial prospects of treatment for its lead drug candidate.
Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022
Short Hills, New Jersey--(Newsfile Corp. - September 7, 2022) - Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab ("LENZ®"), a f...
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humanigen, Inc. ...
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors
Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-s...
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $HGEN #HGEN--The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
Humanigen Reports Second Quarter 2022 Financial Results
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that ne...
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class ...
HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study - What's Next
HC Wainwright downgraded Humanigen Inc (NASDAQ: HGEN) to Neutral from Buy and removed the price target based on the removal of COVID-19 from lenzilumab projections and the lack of near-term catalysts ...
Humanigen's stock tumbles 67% after sharing new clinical data for its COVID-19 treatment
Shares of Humanigen Inc. plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Sciences Inc.'s Ve...
Humanigen's Lenzilumab Disappoints In NIH-Backed COVID-19 Study
Humanigen Inc (NASDAQ: HGEN) has been informed of preliminary topline results from the ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19...
Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' (NIAID...
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen Announces Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 patients with Lenzilumab Guided by C-Reactive Protein
NIH/NIAID Locks ACTIV-5/BET-B Database
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cy...
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cy...
Humanigen Announces Participation and Presentation at Multiple Conferences in June
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cy...